BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company ...

Jabs like Wegovy and Ozempic may cut the risk of life-threatening complications after a heart attack, researchers have ...

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine ...

Povorcitinib 75 mg achieved high-threshold lesion clearance by week 12, including 100% draining-tunnel reduction in 12%–57% and total abscess clearance in 22%–62% of participants. Phase 3 data show ...

T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, ...

Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- ...

Kymera Therapeutics remains focused on pipeline progression despite a Q4 revenue miss and widening net loss, supported by a robust $1.6 billion cash position. R&D investment surged to $316.6 million ...

Can you leave a clinical trial early? Learn your rights, what happens if you withdraw, and how to exit safely without affecting your medical care.

The FDA proposed new guidelines for approving experimental therapies for rare diseases without large group studies.

As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S.

These results suggest that ruxolitinib cream offers high levels of clinical efficacy, including deep and rapid responses, ...